Skip to main content Accessibility help
×
Home

Information:

  • Access
  • Open access
  • Cited by 11

Figures:

Actions:

      • Send article to Kindle

        To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Antipsychotic drugs – information and choice: a patient survey
        Available formats
        ×

        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Antipsychotic drugs – information and choice: a patient survey
        Available formats
        ×

        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Antipsychotic drugs – information and choice: a patient survey
        Available formats
        ×
Export citation

Abstract

Aims and Method

The National Institute for Clinical Excellence (NICE) has issued guidance on the use of atypical antipsychotic drugs and recommended that patients be involved in a discussion about the antipsychotic prescribed to them. We undertook a study to evaluate information provision and patient choice subsequent to the publication of this guidance. Patients were recruited from the South London and Maudsley Trust and interviewed. Case notes were examined for documentation of informed discussions.

Results

Thirty patients were interviewed, of whom 15 claimed to have received no information. Twenty-seven patients felt that they had had no choice in regard to antipsychotic prescribed. None of the patients had documentation in their notes to suggest that they were involved in informed discussions about the antipsychotic they were prescribed.

Clinical Implications

Patients were not involved in decisions regarding the antipsychotic medication prescribed. Practice did not follow the NICE guidance.

The National Institute for Clinical Excellence (NICE) issued guidance on the use of atypical antipsychotic drugs in the treatment of schizophrenia in June 2002 (National Institute for Clinical Excellence, 2002). In this guidance, NICE recommended that the antipsychotic prescribed should be jointly decided upon by the prescriber and the patient, based on an informed discussion, and such a discussion should be documented in the patient’s case notes.

Some studies have been undertaken by various organisations to evaluate issues surrounding informed choice. The National Schizophrenia Fellowship (now Rethink) carried out a survey of mental health users’ views on their medication; the report, A Question of Choice, found that only 38% of users were offered a choice of medication by their doctor and 40% had no written information about the side-effects of their psychiatric medicines (National Schizophrenia Fellowship, 2000). A follow-up survey of people taking antipsychotic medication reported similar findings: only 40% were offered a choice and 50% received written information about possible side-effects (National Schizophrenia Fellowship, 2001). Another study examining the extent to which informed consent was given by long-term psychiatric in-patients found that only a fifth of patients knew the purpose of their medication and one-tenth knew about the side-effects (Brown et al, 2001).

In this study we aimed to evaluate the extent to which patients were provided with information and involved in the choice of antipsychotic prescribed. We also set out to discover the extent to which discussion on choice was documented in case notes.

Method

Patients were recruited from eight acute adult wards over a period of 4 weeks in May 2004. The inclusion criteria were as follows:

  1. diagnosis of schizophrenia, schizoaffective disorder or psychosis-related illness;

  2. antipsychotic medication prescribed for no longer than 6 months;

  3. patient well enough to participate as judged by the nursing staff.

Participants were interviewed by means of an informal discussion with the same interviewer (B.O.). The following information was obtained from each patient during the course of the interview:

  1. form of information received on the antipsychotic the patient was prescribed (e.g. leaflet or verbal);

  2. choices of antipsychotic offered (this was partly determined by the number of antipsychotics from which they felt they could choose);

  3. level of contribution; rated by the patient as none, limited or unrestricted.

Documentation on the choice of antipsychotic, information given and persons involved at the time of discussion was sought from the medical notes. Case notes were searched for the period from a week before the patient began the antipsychotic treatment up to a week after treatment had commenced.

Results

Thirty-three patients were eligible for the study; of these, three refused to be interviewed and the remaining 30 patients with various psychotic disorders were enrolled in the study. A majority (60%) of the patients were diagnosed with schizophrenia and the remaining 40% had various psychosis-related illnesses (Table 1).

Table 1. Demographic details

Item n (%)
Gender
     Female 12 (40)
     Male 18 (60)
Age (years)
    <21 4 (13)
     21-30 5 (17)
     31-40 12 (40)
     41-50 6 (20)
     51-60 2 (7)
    > 60 1 (3)
Ethnicity
     African 10 (33)
     African-Caribbean 8 (27)
     English, White 3 (10)
     Irish, White 5 (17)
     Other (mixed, Asian, etc.) 4 (13)
Diagnosis
     Schizophrenia 18 (60)
     Schizoaffective disorder 5 (17)
     First onset psychosis 2 (7)
     Psychosis (not otherwise specified) 5 (17)
Type of antipsychotic
     Conventional 7 (23)
     Atypical 22 (73)
     Clozapine 1 (3)
Mental Health Act 1983 status
     Informal 12 (40)
     Section 2/3 18 (60)

Information received

Fifteen (50%) patients claimed to have received no information at all (Table 2). One patient had refused the offer of a leaflet and seven (23%) patients received patient information leaflets. One (3%) patient could not remember if information had been received, one claimed not to care and one had received information by attending a pharmacist-led medication group session. Two (7%) patients gave responses classified as ‘other reasons’: one patient claimed he did not like to read, and the other patient received information from his wife. Two patients said they obtained information on their own from the British National Formulary and the Monthly Index of Medical Specialities.

Table 2. Patients’ responses

Response n (%)
Information received
     None 15 (50)
     Leaflet 7 (23)
     Self 2 (7)
     Pharmacist 1 (3)
     Don’t care 1 (3)
     Can’t remember 1 (3)
     Refused 1 (3)
     Other reasons 2 (7)
Choice given
     None 27 (90)
     Between depot and oral 2 (7)
     Free 1 (3)
Contribution made
     None 26 (87)
     Limited 1 (3)
     Unrestricted 3 (10)
Documentation in notes
     Yes 0
     No 30 (100)

Choice of antipsychotic

The majority of patients (27; 90%) felt they had not contributed to the choice of drug because the antipsychotic prescribed for them was chosen entirely by the prescriber or the medical team. Two (7%) patients had been offered the choice between a depot antipsychotic and an oral antipsychotic. One patient felt he had a free choice because he chose the antipsychotic he was prescribed.

Contribution to choice of antipsychotic

Three (10%) patients felt that their contribution to the choice of treatment was unrestricted. One patient felt he was partly involved, whereas 26 (87%) patients felt they were not involved at all in the decision.

Documentation in notes

None of the patients had documentation in their notes to suggest that the benefits and side-effects of their medication were discussed with them. In one case, it was documented in the notes that the offer of an antipsychotic information leaflet had been turned down by the patient.

Discussion

Our results show that the majority of patients did not feel involved in discussions about their antipsychotic medication and only a small number were given the opportunity to choose the antipsychotic prescribed by them. Also, documentation of discussions about medication in the patients’ notes was quite poor and did not appear to reflect information given by patients.

We did not examine the reasons for not allowing patients informed choice, but both patient and prescriber factors are probably relevant. For instance, nursing staff often commented that patients sometimes turned down information leaflets offered to them, possibly because of lack of insight into their illness at the time. Also, some patients were considered to be incapable of participating in an informed discussion at the point of prescribing. In such situations, NICE advises that an advocate or carer should be involved and efforts made to include them in decisions with full documentation in the notes. It is also noteworthy that there are some situations in which the choice of the antipsychotic prescribed may be determined by the nature of the illness. In treatment-resistant schizophrenia, for which clozapine is the only effective treatment, a patient might be discouraged by the lack of options.

The majority of the participants in this evaluation felt they were not given sufficient - or, in some cases, any - information about the antipsychotic prescribed. Information is sometimes withheld from patients because of concerns about non-adherence. Contrary to this belief, informing patients of the long-term side-effects of antipsychotics, such as tardive dyskinesia, seems to have little impact on adherence (Chaplin & Kent, 1998). A few of the patients claimed to have had to ask for an information leaflet as this was not voluntarily offered to them. Leaflets for the various antipsychotics are readily available through the trust’s intranet system which is accessible to ward staff. It remains unclear whose responsibility it is to provide these leaflets to the patients. Another area of concern is the uncertainty that the desired outcome will be achieved by providing leaflets to patients. It is assumed that information leaflets will adequately inform patients about their medication. One patient had no interest in reading the information sheet offered to him, and another could not read. Such patients and others might not benefit from reading a leaflet, but may require oral information. Whatever the reasons for our findings, there are clear implications for the training of senior house officers - those most likely to prescribe antipsychotics and with the best opportunity to discuss choice with patients.

Documentation of discussions with patients is important in this and other areas of practice. It is possible that patients interviewed in this study gave a distorted account of their contribution to drug choice. Many might have had negative feelings about their diagnosis, their leave status or their need for treatment. These feelings might have affected their recollections or reporting of events. It is also possible that the participants simply forgot discussions taking place at the stressful time of admission and first prescription. Without any entry in the case notes, it is impossible to evaluate any discrepancy between patient recall and actual events. It is recommended by NICE both that patients contribute to choice and that this contribution is recorded.

This evaluation has highlighted some interesting questions around the subject of ‘choice’: for instance, what do patients understand by choice? Often choice was interpreted as being a choice between antipsychotic treatment and no treatment at all. Only one patient was considered to have a free choice because he chose for himself the antipsychotic he was prescribed. However, it was unclear whether his choice was based on an informed discussion, because he simply asked to be given the same medication as his wife. The majority of the other patients felt that they were not offered a choice of antipsychotic. The two patients given a choice between a depot antipsychotic and oral antipsychotics were not offered the full range of antipsychotics available. Even though these patients had a choice between two antipsychotics, their choice was obviously restricted.

There are many good reasons for informing patients about medicines and for allowing them to contribute to drug choice. Not the least of these is that prescribers and patients have very different views about drug side-effects and tolerability (Day et al, 1998). Moreover, involving patients in informed discussion is likely to encourage a trusting relationship between prescriber and patient and perhaps to improve adherence - patients are probably more likely to take a medicine they have chosen themselves. This is the essence of concordance - an agreement. It is not clear why prescribers are reluctant to take on this recommended practice, but further research in this area is certainly called for. In particular, a wider survey of practice would establish the generalisability or otherwise of these results obtained in a single unit.

Declaration of interest

None.

References

Brown, K.W., Billcliff, N. & Mccabe, E. (2001) Informed consent to medication in long-term psychiatric in-patients. Psychiatric Bulletin, 25, 132134.
Chaplin, R. & Kent, A. (1998) Informing patients about tardive dyskinesia. Controlled trial of patient education. British Journal of Psychiatry, 172, 7881.
Day, J., Kinderman, P. & Bentall, R. (1998) A comparison of patients' and prescribers' belief about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica, 97, 9397.
National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: NICE.
National Schizophrenia Fellowship (2000) A Question of Choice. London: NSF.
National Schizophrenia Fellowship (2001) That's Just Typical. London: NSF.